Denali Therapeutics 将来の成長
Future 基準チェック /26
Denali Therapeutics利益と収益がそれぞれ年間23.4%と59.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-34.4% 26.5%なると予測されています。
主要情報
23.4%
収益成長率
26.5%
EPS成長率
Biotechs 収益成長 | 27.3% |
収益成長率 | 59.3% |
将来の株主資本利益率 | -34.4% |
アナリストカバレッジ | Good |
最終更新日 | 01 Nov 2024 |
今後の成長に関する最新情報
Recent updates
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 234 | -377 | -294 | -252 | 11 |
12/31/2025 | 65 | -443 | -437 | -267 | 14 |
12/31/2024 | 23 | -412 | -525 | -335 | 15 |
6/30/2024 | 1 | -420 | -402 | -391 | N/A |
3/31/2024 | 295 | -137 | -425 | -413 | N/A |
12/31/2023 | 331 | -145 | -371 | -358 | N/A |
9/30/2023 | 341 | -124 | -348 | -332 | N/A |
6/30/2023 | 343 | -128 | -321 | -302 | N/A |
3/31/2023 | 101 | -371 | -248 | -231 | N/A |
12/31/2022 | 108 | -326 | -263 | -245 | N/A |
9/30/2022 | 111 | -303 | -254 | -238 | N/A |
6/30/2022 | 112 | -284 | -234 | -222 | N/A |
3/31/2022 | 83 | -286 | -243 | -233 | N/A |
12/31/2021 | 49 | -291 | -220 | -211 | N/A |
9/30/2021 | 353 | 30 | 361 | 368 | N/A |
6/30/2021 | 357 | 56 | 404 | 410 | N/A |
3/31/2021 | 340 | 58 | 415 | 420 | N/A |
12/31/2020 | 336 | 71 | 413 | 416 | N/A |
9/30/2020 | 24 | -228 | -150 | -145 | N/A |
6/30/2020 | 28 | -216 | -183 | -176 | N/A |
3/31/2020 | 26 | -215 | -193 | -176 | N/A |
12/31/2019 | 27 | -198 | -169 | -152 | N/A |
9/30/2019 | 148 | -66 | -27 | -11 | N/A |
6/30/2019 | 135 | -55 | -30 | -15 | N/A |
3/31/2019 | 133 | -52 | -19 | -14 | N/A |
12/31/2018 | 129 | -36 | 47 | 50 | N/A |
9/30/2018 | 3 | -137 | -64 | -61 | N/A |
6/30/2018 | 2 | -123 | -51 | -49 | N/A |
3/31/2018 | 1 | -91 | N/A | -24 | N/A |
12/31/2017 | N/A | -88 | N/A | -77 | N/A |
9/30/2017 | N/A | -85 | N/A | -77 | N/A |
6/30/2017 | N/A | -93 | N/A | -76 | N/A |
3/31/2017 | N/A | -90 | N/A | -75 | N/A |
12/31/2016 | N/A | -87 | N/A | -72 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: DNLIの収益 ( 59.3% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。
高い収益成長: DNLIの収益 ( 59.3% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: DNLI 3 年以内に赤字になると予測されています。